Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration...
Read moreAbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal...
Read moreAbbVie , a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of...
Read more- IMBRUVICA ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN KEY ENDPOINTS INCLUDING REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH VERSUS...
Read more• New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694*...
Read moreClinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK),...
Read moreClinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma Syndax Pharmaceuticals,...
Read moreMerck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an...
Read more• 11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro...
Read moreYour Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
